Phase 3, randomised double-blind, placebo-controlled, multicentre trial assessing the impact of Lp(a) lowering with pelacarsen on major cardiovascular events in patients with established cardiovascular disease
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
